Jason Snyder • December 22, 2025

DOH Seeking SUD Treatment Providers’ Experience With Medetomidine

Author

Jason Snyder

Date

December 22, 2025

Share

Medetomidine is a veterinary sedative, similar to xylazine, that was first found in Philadelphia’s drug supply in May 2024

Since then, it has spread across Pennsylvania. Medetomidine is 100-200 times more potent than xylazine and can cause longer-lasting sedation, low heart rates, and more severe withdrawal symptoms. It is not an opioid but is found in the illicit drug supply.


The Pennsylvania Department of Health (DOH) is seeking information about complications associated with medetomidine in the drug supply. DOH is particularly interested in SUD treatment providers’ responses to the following.

  • Are you seeing an influx in clients presenting with worsening withdrawal symptoms (e.g., racing heart, severe nausea, high blood pressure, tremors, confusion)?
  • Are you seeing an increase in clients leaving against medical advice?
  • Have you had to send clients to the hospital because their symptoms required a higher level of care?
  • Are there any other changes you are noticing in your community that you think DOH should know about?


You can email your responses to DOH Senior Harm Reduction Technical Advisor Roseanne Scotti or RCPA SUD Treatment Policy Director Jason Snyder.

PA ODP logo with dark blue border
By Tim Sohosky May 29, 2026
On Thursday, May 28, the Office of Developmental Programs (ODP) provided an update to the Medical Assistance Advisory Committee (MAAC) regarding current policies and upcoming regulatory changes following a recent Commonwealth Court decision. On February 17, 2026, the PA Commonwealth Court issued a decision in Dunkelberger v. Department of Human Services that determined that ODP’s limitations on provider model services (specifically the 40/60-hour caps and 90-day travel maximums) were null and void. The decision was based on process rather than policy validity; the Court found that these limitations were not properly promulgated as regulations in accordance with the Commonwealth Documents Law and Regulatory Review Act. To maintain a balanced approach between flexibility and oversight, ODP is moving forward with the following actions: Regulatory Amendments: ODP will amend regulations to establish formal authority for setting service delivery limits that support individual welfare and program integrity. Self-Directed Model Agreements: ODP has already modified agreements for self-directed models to clarify limits on overtime, combined relative service provision, and travel restrictions. Travel Restrictions: Due to the inability to monitor services effectively over long distances, service provision will now be limited to Pennsylvania and contiguous states. Waiver Changes: ODP will seek modifications through the amendment process to the Consolidated, P/FDS, Community Living, and Adult Autism Waivers to include: New requirements for agencies providing IHCS and Companion services to disclose a DSP's relationship to participants; and Strengthened programmatic oversight and integrity measures. Life Sharing Alternative: For participants requiring more than 60 hours of paid care from a relative, the Life Sharing (24/7) service model remains the recommended alternative. ODP anticipates a public comment period for these proposed waiver changes beginning in January 2027.
Yellow screen with the words
By Cathy Barrick May 28, 2026
The Office of Developmental Programs (ODP) has shared ODPANN 26-039 . The purpose of this communication is to provide updated details about the Residential Performance-Based Contracting (PBC) Pay-for-Performance (P4P) initiatives for Fiscal Year 2026/27. Updates are provided in red . Please review the announcement for more details. Visit here to access the Pay for Performance (P4P): Residential Rural Capacity Expansion Plan template .